A recent report by Moody’s Investor Service found that following regulatory crackdowns on the pharmaceutical market, the generic drug industry will likely experience rapid consolidation in the near future. According to Moody’s, the recent US Supreme Court decision, which found that drug makers can face lawsuits regarding pay-for-delay agreements, will lead to an influx of Federal Trade Commission scrutiny over the industry as well as class action litigation, many such cases have been on hold since before the Supreme Court ruling. The result, said Moody’s, means threats of large liabilities that – along with other factors – could lead generic drug makers to consolidate as purchasers and regulators seek damages. The report cites last week’s decision by Teva Pharmaceuticals to settle over such an antitrust case for $485 million.
Full Content: Forbes
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI